Today we're going to be talking about these seven penny stocks that will be spiking in March 2019. The reason that I could say this confidently is because the companies on this list literally tell you when these price action will have massive movement. They do this by releasing dates that they will have FDA approvals trial results. They also draw many hits and clues as to whether their data will be positive or negative.

So I'm going to be presenting all of the data as well as my opinion on each of these stocks. but it's up to you to do your own research. The great thing is the data presented at this video will serve as a great starting point. Anyways, you know a lot of work goes into researching these stocks on these videos.

So in return the only thing that I ask of you that you hit that beautiful like button. And also if you see value in the following video, subscribe for more short sweet and simplified videos on how to trade the stock market. Ok so the first stock is re pH there PDUFA date aka FDA approval date is on March 24th. That means that this is the day that we see whether or not the FDA has approved their drug for pain treatment.

So the key here is to understand that 80% of FDA approvals end in success. This is something that a lot of traders don't know for some reason and a lot of people speculate on whether or not they're going to succeed and they don't realize that 80% of them do succeed. Now, the reason that these drugs succeed a majority of times is because they have to go through a series of intense phase trials before submitting their applications for approvals. The reason that these stocks go up even after phase Trowell passages is because people will anticipate them going through and getting that FDA approval after they pass each stage.

So by the time it gets to the FDA approval stage, a lot of people are a lot more confident that they're going to get approved. But this gives them so many chances to fail that it becomes increasingly unlikely for them to pass all of these phase trials regulated by the FDA and then fail at the actual FDA approval. That being said, 20% still do fail. Now, this varies year over year, but if you factor in that, 80% of FDA approvals ended in success.

Even if you bet on the entire industry and cut your losers quickly, there would be tremendous opportunities to profit. But of course, we don't blindly bet on stocks here. We also employ risk management techniques such as making sure to get in at good entry points, so if you actually learn technical analysis and figure out what to look for, you should be able to improve those odds even more with these thoughts. So going back to the price action: the stock price got beat down in May but has recovered a lot of its share value.

The key here is that we see this pretty consistent run up on the year where it gives some of these opportunities to buy in at push back when the are sighs marked at or below fair value and then add to our upward potential as the stock continues to climb. So if we see a discounted opportunity to buy in and see those signs of a reversal that could signal a sign of a continued uptrend in anticipation of that FDA approval. Of course, the approval might already be factored in to the stock price somewhat so that it could hurt our upward potential. And thus, it's important that we find a specifically good entry point, such as looking for that oversold on the RSI.

On the next talk is LX Rx. they'll have their FDA approval results on the 22nd of March for their diabetic drug. Now, this one is promising, specifically because we have this massive amount of upward potential compared to a relatively low amount of downward potential. That means that if we see a positive result, there's a high probability that we could see, even conservatively speaking, a doubling of share price.

That being said, the analyst slash monkeys hold mixed opinions, but we do see high price targets all the way to 26 dollars and the average price target at $19 across analyst firms. Now that seems pretty idiotic in my opinion, since that would require something like a 400% increase in a shattering above its all-time three-year high in 1962. Yet this is the consensus amongst most large analysts. but you know what they say.

They say monkey-see monkey-do and hopefully see B price action benefit from this insane price target. That being said, I'm pessimistic about the long term capabilities of these stocks, so as always, we're going to want to find the perfect entry point somewhere close to oversold on the horror slide while also displaying the signs of an upward reversal that we are looking for. By the way: I have a video two steps of a stock reversal. I'll put a link in the description below as well as some other videos that have great tips on how to manage risk and how to find signs of a reversal and how to day trade in between creating general.

Okay, the next stock is M and L o They released their phase two data back in October it says December but they released it earlier than their original plan, but they will be presenting on March second, which gives them an opportunity to pump their stock. This company is a fun one because it has a history of being accused of hiding data in order to apparently entice investors leading all the way back to its IPO but it also has a lot of big-name institutional investors such as JP Morgan which I'll discuss more after introducing this company. So the first thing you need to understand is that this company's primarily focused on this drug and figuring out what it can be used to treat. The data was for their tests back in October on the treatment of Reef out of refractory chronic cough.

Sadly for the company that failed to demonstrate any benefits of the drug and instead of treating costs instead left the shareholders coughing up their money. Anyways, the reason this is relevant is because on March 2nd they are going to be presenting at a new conference in a completely different sector of Medicine which is dermatology. Now remember they just failed with this very same drug in one sector and now it's being attempted in another. So this means they have even more pressure to rebrand that very same drug as a new winner in a completely different sector.

So this presentation on the second will be their opportunity to present and pipe up the drug before its phase 3 data is presented this year. But if only there was a way to figure out whether or not the insiders and institutional investors think this is going to be a successful presentation. Oh wait, there is. So if we completely throw out the fact that FML O has been silently climbing on no news since the start of the year and time leading up to the presentation and the phase 3 data release which in and of itself is telling, we can then look into the actions and types of investors who are taken in holding positions in this company.

So we see big names like JP Morgan Blackrock and Vanguard taking positions. In the case of JP Morgan, we see a massive increase in hundreds of percentage points. So this has a lot of big bets for such a tiny pharmaceutical company with a recent flop on its track record. So Zacks Investment Research changed it from a hold to aid buy and Cantor Fitzgerald is also reiterating there by ranking and setting a price target at $25 which I also think is a tad bit insane to set since we have no idea how the trials will go.

but nonetheless, monkeys will be monkeys. But anyways, this shows that the monkeys are generally ready to hop on this stock which honestly doesn't mean much to me and probably doesn't mean much to you either. but I know a lot of people like it when I show analyst opinions. So in summary, we have a company that is recovering from a massive flop and failed trial which has been pretty successful at driving investors slowly back into it.

It crashed from 12 to 3 74 which was honestly pretty damn harsh and was likely partially an overreaction, but since it hit new lows, its doubled while not seeing any compelling fundamental reasons for doing so. My guess is that the perception will continue to improve as the presentation approaches, and then after we'll start seeing some media coverage that will likely increase the volume and the price of the stock, it's anybody's guess whether or not phase data will be positive or negative. My guess is that people within the company don't even have the full picture yet. and there hasn't been any insider purchases since last year, so no tips for us.

Nonetheless, this stock is bound to see some volatility this month and I bet we'll see some great buy entry points. Okay, the next stock is E I Gr. so they will be presenting their phase 2 data at the next Endo conference on March 25th. Now the first thing I'll say is this is the company that back in May they were sort of the darling of the sector.

That means from the success of their drug that helped children with progeria. Now that's awesome And I'm not saying anything bad about the company, but we don't want to focus on what they're doing as traders. We have to focus on the price action and the fundamentals and how that's going to make or break the stock price. So focusing on the price action.

We did see an overreaction and then a subsequent sell-off, but this wasn't just an overreaction, it was a huge spike from 8 to 218 dollars in the manner of like 2 weeks. with most of these spike happening in the first few days leading up to the announcement. so obviously people were already expecting them to be successful. But the run-up tells us now that it has this perception back spike ability factor that I like to talk about.

What this establishes is that yes, this stock is prone to having massive run ups in a short time period based on perception alone as well as anticipation. Now you might listen to that statement that I just made and then look at this chart and be like but wait, Charlie I Thought you said that this increase in share price was due to this company's success with Progeria. Now that's true for part of the run-up, but we didn't know about that until halfway through the run-up right? We didn't know that they were successful yet, and the price had already begun, had already halfway trended upwards, and then the next few days we continue to see this upward push, which means even if we heard about the news the day of, we still had opportunities to buy it. But we saw this overreaction and subsequent correction that we see with nearly every stock.

nonetheless. but the reason the spike is significant is because it not only confirms the spiked ability of the price action, but it also declares precedent for how prone investors are to overreacting with this company and it's news and likely events. It also declares a higher level of upward potential, which makes this position a lot more equitable. I Often talk about how a recent highs tend to have a sort of like gravitational pull, which is mostly because of the fact that once a stock starts up trending, the investors and traders all freaked out thinking it could go all the way back up to where it sold off from.

And that adds to the effect of the run-up. But the problem here is there. It really isn't that much more room to run. It looks like, what a little over $4 So that's not a great amount of upward potential compared to the vast amount of downward potential.

So what I look for in terms of taking a position is at least some form of a pushback, preferably to oversold, but also showing signs of an uptrend such as that building of momentum. Also I Don't know that we'll get this chance, but if we do see a dip back down to support at $9 a share, that looks like an awesome entry point for us. Okay, so you ROV will be releasing phase 3 data in March Their drug is for treatment of overactive bladder, but don't race to the bathroom quite yet. The reason that we are watching them is because their phase 3 data is due in March and they've been slowly running up in anticipation.

Now in terms of price action, it's sort of the same thing as the last stock. A lot of downward potential, but not a lot of upward potential Comparatively also show this sell-off and recovery pattern. But the thing is that since we have seen this increase in share price, we also have a huge increase in short positions, which could provide some rocket fuel if we do see the share price increase. but I'll go into that a bit more later now.

The trend that does worry me is that while we saw this massive amount of institutional buying in Q3, we now see more outflows than inflows for the company. Now, this obviously pales in comparison to the influence in Q3, but we see more outflows in Q4 than inflows, which is worrisome on at least on some level. But it's not as polarized as it seems. It makes sense that there would be substantially more in Q3 and Q4 because that's after the company became publicly traded and did its institutional fundraising rounds.

But this outflow specifically after this increase in share price shows and willingness to abandon shares for a quick profit, which doesn't show much confidence in the overall stalk on behalf of the institutions. Now, Quarter One has seen some pretty solid gains running up to the release of their newest phase data. Now, a lot of people tend to think that I use running up before phase data as sort of like a quiet confirmation that the release is going to be positive. but obviously I'm a trader and not a psychic and I can't predict whether a report is going to be positive or negative.

I don't even really make an attempt to I just look at what the insiders are doing and try to figure out you know what is more likely based on what they're doing. If you could figure out what the insiders and everybody else thinks, you could take that and identify a way to leverage that knowledge to your benefit in predicting what's going on. So in this case, I Usually start by looking for what the insiders are doing. We haven't seen much movement in terms of this quarter, but in the last 12 months we've seen a lot of insider buys.

But again, this doesn't mean jack because this was the beginning of the option for insiders to buy in, so not really a strong indicator in either direction. So instead we're going to have to look a bit deeper. So if we pull up the actual insider list, we see the list of individual investors within the company. Now the ones that I care about are the ones that aren't defend Share and capital management firms.

You can clearly see which ones are and aren't by the names. Now there's two individuals who own a chunk of the company, but there's also one company that is a direct owner. So these are the three owners that are worth looking into. If I look into the direct owner row.

Rows Nint or Whatever Sciences is a pharmaceutical company that licenses late stage drug candidates and develops them through subsidiaries. Now the key here is that this direct partnership offers some sort of validity for the funding came over at you wrong. Now, the reason this is relevant is because under the surface you rob at Best is a sketchy company incorporated in Bermuda with absolutely no track record. All they have is the promise of their face trials.

Yet, they've been able to convince large investment banks to take positions. Now, investment banks the strategy behind most investment bases. They don't want to worry about whether or not a trial is successful. They want reasonable assurance that they'll be able to make a profit regardless of the result of the trial.

So in order for a company like you off to convince them to take a position, they're going to need to figure out a way to paint themselves in a new light and a direct stake from Roy's net. Sciences Firm with a solid track record helps provide that validity. At the same time though, the company needs to produce a return. Dauntless And how these companies do, that is by transforming perception.

Even if the trial results fail, these companies will often in point tactics to increase their perceived value, such as targeted press releases talking about future or continuing phase data or other phase trials that they're working on. And they employ targeted press releases and a lot of them even hire certain media PR firms to prop up the stock and prop up the perception. But there are really only two scenarios that I could see playing out for you. Wrong this month.

Now, as it gets closer to trial data released, the stock price is continuing to gain and what we see is a start of an increase in shorting as well. The reason the increase in short positions is good is because if we continue to see more short and we also have positive trial results, will see a short squeeze like none other. as Shorts rushed to cover their position, the price will multiply its momentum and offer opportunity for traders to profit. But again, you may notice that most of my analysis on the stock was negative.

That's because I don't believe in the long-term viability of these companies on average, but I do believe in their short term profitability as traders. That being said, there's a very high chance that regardless of the phase data results, we'll see good execution points this month. The key here is identifying again the key here. I Don't want to sound like I'm beating a dead horse with this, but the key here is identifying where to get in and get out and the best way to do that is by pairing the fundamentals to the technicals.

I have tons of videos on technical analysis so I highly recommend you check those out if you having a hard time managing your risk. Okay so the next stock is Fwp. so Fwp has been selling off since its spiked in May Now they said they will be releasing their phase 3 data this quarter but it hasn't come out yet, so we should see it in March Since that's the last month of the quarter, they're working on something for hormone for hormone deficiency and children. The reason that I like the stock is because it has massive amount of upward potential from 138 all the way to 445.

But the key here is to watch for irregularities in the stock price because at any time we could see that phase data released. That being said, I think the best play with this is getting that pattern confirmation that we talked about in terms of finding signs of a reversal. This one could run all the way up to 445, but it's key to get in when we see it at least at the fair value on the RSI I Have a whole video on the RSI if you're confused of what I'm talking about. I'll put the lead description below, but we want to see more upward potential than downward potential since we don't know exactly when or even what is going to be in the data.

Okay, so these seventh penny stock is a lot more speculative than the other six since it's earlier in the development process, but the advantage here is that we see a huge sell-off with some early signs of a potential uptrend. The thing I like about this is that we are within 30 cents of the bottom and we almost have five dollars of upward potential. That's a huge amount of opportunity in our favor. In terms of fundamentals, if we see some positive news this month, or even the perception of positive news, we could see an overreaction.

Of course, positive news in this type of category won't equate to the reaction of the other stocks, but it could have the spiraling effect as a catalyst did any massive amount of upward potential well. Vee Monkeys are generally looking at this stock in a fair light, so take that as you will. I Also want to finish this off with one last stocks that I didn't include in the number count. so this is Rh HBY and I didn't include it in the number account because it's far from being a penny stock.

yet it's going to have an FDA decision on March 12th unless I think it's totally worth watching. It also has pretty promising price action, but it might be a bit overextended anyways. if you are wondering how I found these stocks and research them I Literally used Biopharma Catalyst Calm. then Googled and new.

Search each of these thoughts until I got the answers. I'll link to V Bio calendar in the description below if you'd like to do this research yourself I Highly recommend doing it yourself as well. But just to reiterate about the stocks on this list, these aren't stocks to buy and hold with no apparent plan. These are stocks that will provide volatility and price action that weren't taking positions while also focusing on techniques for managing risk and spotting reversals.

90% of my videos are on these topics, so if you're struggling y'all just look through the channel. I Think you'll find something that will provide value for you anyways I Hope this video was helpful. If you have any questions, you can join our zip trader circle Facebook Group or comment below. Anyways, have a great day folks and I'll see you in the next video.